1. Dumont M, Beal MF. Neurorotective strategies involving ROS in alzheimers disease. Free Radic Biol Med 2011; 51(5): 1014-26.

2. Ferreira ME, de Vasconcelos AS, da Costa Vilhena T, da Silva TL, da Silva Barbosa A, Gomes AR, et al. Oxidative stress in alzheimers disease: should we keep trying antioxidant therapies? Cell Mol Neurobiol 2015; 35(5): 595-614.

3. Khanahmadi M, Farhud DD, Malmir M. Genetic of Alzheimer’s Disease: A Narrative Review Article. Iran J Public Health 2015; 44(7): 892.

4. Ovsepian SV, Herms J. Drain of the brain: low affinity p75 neurotrophin receptor affords a molecular sink for clearance of cortical amyloid beta by the cholinergic modulator system. Neurobiol Aging 2013; 34(11): 2517-24.

5. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215(4537): 1237-9.

6. Rabiei Z, Rafieian-kopaei M, Heidarian E, Saghaei E, Mokhtari S. Effects of Zizyphus jujube extract on memory and learning impairment Induced by bilateral electric lesions of the nucleus basalis of meynert in rat. Neurochem Res 2014; 39(2): 353–60.

7. Nyakas C, Granic L, Halmy LG, Baner Jee P, Luiten G. The basal forebrain cholinergic system in aging and dementia rescuing cholinergic neurons from neurotoxic amyloid βA-42 with memantine. Behav Brain Res 2011; 221(2): 594-603.

8. Popović M, Popović N, Jovanova-Nesić K, Bokonjić D, Dobrić S, Kostić VS, et al. Effect of physostigmine and verapamil on active avoidance in an experimental model of Alzheimers disease. Int J Neurosci 1997; 92(1-2): 87-93.

9. Salamone JD, Beart PM, Alpert JE, Iversen SD. Impairment in t-maze reinforced alternation performance following nucleus basalis magnocellularis lesions in rats. Behav Brain Res 1989; 13(1): 63-70.

10. Peng W, Yang J, Yang B, Wang L, Xiong XG, Liang Q. Import of statins on cognitive deficits in adult male rodents after traumatic brain injury: a systematic review. Biomed Res Int 2014; 2014: 13.

11. Dolga AM, Nijholt IM, Ostroveanu A, Ten Bosch Q, Luiten PG, Eisel UL. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis 2008; 13(2): 111-22.

12. Li R, Xu D, Ma T. Lovastatin suppresses the aberrant tau phosphorylation from FTDP-17 mutation and okadaic acid-induction in rat primary neurons. Neuroscience 2015; 294: 14-20.

13. Dabir N, Moazedi AA, Haghparast A, Khajepour L, Akhoond M. Effects of estrogen therapy on cognitive performance deficit induced by nucleus basalis magnocellularis lesion: animal model of alzheimers disease. J Isfahan Med Sch 2016; 34(370): 64-73.

14. Daneschvar HL, Aronson MD, Smetana GW. Do statins prevent Alzheimer's disease? A narrative review. Eur J Intern Med 2015; 26(9): 666-9.

15. Mans RA, Chowdhury N, Cao D, Mcmahon LL, Li L. Simvastatin enhances hippocampal long-potentiation in C57BL/6 mice. Neuroscience 2010; 166(2): 435-44.

16. Chen G, Zhang S, Shi J, Ai J, Hang C. Simvastatin reduces secondary brain injury caused by cortical contusion in rats: possible involvement of TLR4/ NF-кβ pathway. Experimental Neurol 2009; 216(2): 398-406.

17. Chen SF, Hung TH, Chen CC, Lin KH, Huang YN, Tsai HC, et al. lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury. Life Sci 2007; 81(4): 288-98.

18. Chauhan NB, Gatto R. Restoration of cognitive deficits after statin feeding in TBJ. Res Neurol Neurosci 2011; 29(1): 23-34.

19. Szigeti C, Bencsik N, Simonka AJ, legradi A, Kasa P, Gulya K. Long term effects of selective immunolesions of cholinergic neurons of the nucleus basalis magnocellularis on the ascending cholinergic pathways in the rats: a model for alzheimers disease. Brain Res Bull 2013; 94: 9-16.

20. Mendoza-Oliva A, Ferrera P, Fragoso-Medina J, Arias C. Lovastatin differentially affects neuronal cholesterol and amyloid-β production in vivo and in vitro. CNS Neurosci Ther 2015; 21(8): 631-41.

21. Montero-Pastor A, Vale-Martı́nez A, Guillazo-Blanch G, Martı́-Nicolovius M. Effects of electrical stimulation of the nucleus basalis on two-way active avoidance acquisition, retention, and retrieval. Behav Brain Res 2004; 154(1): 41-54.

22. Moazedi AA, Mosavi M, Chinipardaz R. The effect of estrogen on passive avoidance memory in an experimental model of Alzheimer disease in male rats. Physiol Pharmacol 2011; 14(4): 416-25.

23. Luine VN, Frankfurt M. Estrogen facilitate memory processing through membrane mediated mechanisms and alterations in spike density. Front Neuroend 2012; 33(4): 388-402.

24. Davis CP, Franklin LM, Johnson GS, Schrott LM. Prenatal oxycodone exposure impairs spatial learning and/or memory in rats. Behav Brain Res 2010; 212(1): 27-34.

25. Cosquer B, Vasconcelos AP, Frohlich J, Cassel JC. Blood-brain barrier and electromagnetic fields: effects of scopolamine methylbromide on working memory after whole body exposure to 2.45 GHZ microwaves in rats. Behav Brain Res 2005; 161(2): 229-37.

26. Liu P, Bilkey DK. The effect of NMDA lesions centered on the postrhinal cortex on spatial memory tasks in the rat. Behav Neurosci 2002; 116(5): 860-73.

27. Mallet PE, Beninger RJ, Flesher SN, Jhamandas K, Boegman RJ. Nucleus basalis lesions: implication of basoamygdaloid cholinergic pathways in memory. Brain Res Bull 1995; 36(1): 51-6.

28. Liu AK, Chang RC, Pearce RK, Gentleman SM. Nucleus basalis of mynert revisited: anatomy, history and differential involvement in alzheimers and parkinsons disease. Acta Neuropathol 2015; 129(4): 527-40.

29. Zahedi M, Hojjati MR, Fathpour H, Rabiei Z, Alibabaei Z, Basim A. Effect of rheum ribes hydro-alcoholic extract on memory impairments in rat model of Alzheimer disease. Iran J Pharm Res 2015; 14(4): 1197-206.

30. Gratwicke J, Kahan J, Zrinzo L, Hariz M, Limousin P, Foltynie T, et al. The nucleus basalis of mynert: a new target for deep brain stimulation in dementia? Neurosci Behav Rev 2013; 37(10 Pt 2): 2676-88.

31. Givens B, Olton DS. Local modulation of basal forebrain: effects on working and reference memory. J Neurosci 1994; 14(6): 3578-87.

32. Contestabile A, Ciani E, Contestabile A. The place of choline acetyltransferase activity measurement in the cholinergic hypothesis of neurodegenerative disease. Neurochem Res 2008; 33(2): 318-27.

33. Mesulam MM. Some cholinergic themes related to alzheimer,s disease: synaptology of the nucleus basalis, Location of m2 receptors, interaction with amyloid metabolism and perturbation of cortical plasticity. J Physiol Paris 1998; 92(3): 293-8.

34. Coccamo A, Fisher A, Laferla FM. M1 agonists as a potential disease-modifying therapy for Alzheimers disease. Curr Alzheimer Res 2009; 6(2): 112-17.

35. Yamin G. NMDA receptor dependent signaling pathways that underlie amyloid beta protein dis ruption of LTP in the hippocampus. J Neurosci Res 2008; 87(8): 1729-36.

36. Zhao Z, Zhao S, Xu N, Yu C, Guan S, Liu X, et al. Lovastatin improves neurological outcome after nucleus basalis magnocellularis lesion in rats. Neuroscience 2010; 167(3): 954-63.

37. Park IH, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, et al. Lovastatin enhances A production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 2003; 24(5): 637-43.

38. Baytan SH, Alkanat M, Okuyan M, Ekinci M, Gedikli E, Ozeren M, et al. Simvastatin impairs spatial memory in rats at a specific dose level. Tohoku J Exp Med 2008; 214(4): 341-9.

39. Douma TN, Borre Y, Hendriksen H, Olivier B, Oosting RS. Simvastatin improves learning and memory in control but not in olfactory bulbectomized rats. Psychopharmacology (Berl) 2011; 216(4): 537-44.